|Bid||5.29 x 1100|
|Ask||5.34 x 4000|
|Day's Range||5.21 - 6.00|
|52 Week Range||3.76 - 10.95|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||17.63|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The most recent earnings report from Aphria (APHA) was underwhelming, as it continues to experience heavy losses. While its earnings were up, they still failed to meet already mild expectations.It's no secret cannabis companies based in Canada are going to continue to experience weak growth over the next couple of quarters. Even so, in the case of Aphria, if it is able to successfully execute in several segments, it could surprise to the upside throughout calendar 2020.Recreational potA potentially major catalyst for Aphria will be if it can continue to increase market share in Ontario, which is by far the largest market in Canada. It has managed to boost its share of recreational pot from 6 percent in fiscal 2018, to an impressive 14 percent as of this writing.For most Canadian companies, the commitment by Ontario authorities to increase the number of retail cannabis stores on a monthly basis should provide a resultant increase in revenue. If it manages to follow through on its promises, and Aphria can at least maintain its share, and possibly increase it, it will be a nice catalyst for the company.It needs to be understood that it's going to take time because of the gradual opening of new stores in the province. There should be at least 20 stores a month opened, starting at latest in April 2020.Its Riff and Good Supply brands are two of the more recognized recreational brands in Canada, and should continue to do well as legal demand for pot increases.DerivativesDerivatives could play a big part in the potential surprise performance of Aphria in 2020. The first thing to note is if the company does retain or grow recreational share, it should generate significantly more revenue because of higher prices. It also should result in wider margins and a decline in losses.Other potential surprises could come from a successful launch of infused beverages, and if Alberta and Quebec decide to remove existing bans on vapes. Of the two, I'm not as convinced about the market demand for infused beverages yet, and of course the bans must be removed for it to make a difference.These two aspects of derivatives need to be closely watched, but for now, they can't be counted on.GMP certificationThe company announced it has received GMP certification from EU, which will allow it to start shipping medical cannabis products to the trading bloc. The company stated it expects to start shipments to the EU by the latter part of May 2020.With Germany being the largest market in the EU, it's the most important. Expectations are that within a few years it could have as many as 1 million medical cannabis patients in the country. Combined with other EU markets, it represents a significant opportunity to sustainably increase revenue and earnings.Germany is also important because it has among the highest prices for medical cannabis, and also has insurance pay for between 60 and 70 percent of usage. That's expected to improve in the years ahead.Consensus VerdictWall Street anchor a bullish perspective on the cannabis player, as TipRanks analytics showcase APHA as a Buy. Based on 6 analysts polled in the last 3 months, 4 are bullish on Aphria stock, while 2 remain sidelined. The 12-month average price target stands tall at $6.89, marking a nearly 30% upside from where the stock is currently trading. (See Aphria stock analysis on TipRanks)ConclusionAlthough there are a lot of things that have to go right for Aphria for it to surprise to the upside in 2020, if it is able to successfully execute in Ontario, successfully introduce some derivative products in Canada, and catch some breaks in Alberta and Quebec, it is going to generate good returns for shareholders.At the least, what I want to see is how it continues to perform in Ontario specifically, as that presents the strongest short-term opportunity in Canada for Aphria and its competitors.The combination of recreational dry pot sales, along with a boost from higher-priced and wider margin derivatives, has the best chance of the company exceeding expectations.I don't expect this to happen in the first calendar half, but in the second half, if Ontario follows through on its promises, and it gets a decent boost from medical cannabis sales in the EU, it has a good chance of turning market sentiment in its favor.At this time it's hard to be too optimistic with Aphria because there are some things outside of its control. That said, those things, for the most part, will be resolved going forward, and as they improve, and if Aphria can execute as they improve it should start to enjoy solid growth and provide a visible path to sustainability.To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Aphria Inc. (TSX:APHA) (NYSE: APHA) announced Friday it has agreed to receive a strategic investment from an institutional investor. Under the agreement, the investor will buy 14.04 million Aphria’s units with a price of CA$7.12 ($5.42) per unit for a total of CA$100 million in gross proceeds. Each unit consists of one Aphria’s common share and one-half of one common share purchase warrant of Aphria.
Canadian cannabis company Aphria Inc. said Friday it has entered an agreement to receive a C$100 million (76.2 million) investment from an unnamed institutional investor. The investor purchased 14 million units of the company priced at C$7.12 per unit, the company said in a statement. Each unit is comprised on one common share and one-half of one common share warrant, entitling the holder to purchase a share at a price of $9.26 for 24 months after the closing date. Proceeds of the deal will be used to finance international expansion, working capital and for general corporate purposes. U.S.-listed hares rose 3.8% premarket on the news, but are down 17% in the last 12 months, while the S&P 500 has gained 26%.
LEAMINGTON, ON , Jan. 24, 2020 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) today announced that it has entered into an agreement to accept a strategic investment from an institutional investor (the "Significant Investor"), pursuant to which the Significant Investor has agreed to purchase 14,044,944 units of the Company at a price of C$7.12 per unit (the "Offering Price") for aggregate gross proceeds to the Company of C$100,000,001 (the "Offering").
Coronavirus, shmoronavirus. The market just doesn't care, with the S&P 500 hitting another new all-time high on Wednesday. That said, let's look at a few top stock trades for Thursday. Top Stock Trades for Tomorrow No. 1: Boeing (BA)Source: Chart courtesy of StockCharts.comBoeing (NYSE:BA) shares remain under pressure, as its 737 MAX woes continue to weigh on investor sentiment. Now though, the stock is breaking through critical range support.Over the past 18 months, only the market-wide, fourth-quarter meltdown was enough to take BA stock below $320 range support. For the past year, any negative 737 MAX news was met by buyers near this mark -- until now.InvestorPlace - Stock Market News, Stock Advice & Trading Tips$320 support gave way this week, and now BA is knifing through its 150-week moving average. For many, BA is a no-touch. That is, until it reclaims $320 range support, or gets to a lower price. In the event of more downside, let's see if BA revisits the 2018 Q4 lows between $285 and $290. * 10 Stocks to Buy as the 2020 Presidential Election Approaches Below puts the 200-week moving average near $265 on the table. Top Stock Trades for Tomorrow No. 2: Aphria (APHA)Source: Chart courtesy of StockCharts.comAphria (NYSE:APHA) stock was one of two cannabis plays that I liked coming into 2020, along with Canopy Growth (NYSE:CGC). APHA is moving nicely on the day, up nearly 8%.The stock is hitting its highest level since it closed at $5.50 on Dec. 13, as it breaks out over that same price and continues to gain after pushing through downtrend resistance (purple line).Bulls would love to see APHA power through the 200-day moving average, although it may very well act as resistance on its first test.If Aphria shares pullback, bulls need to look for two areas of support. The first is $5.50, which had been resistance for months, while the second is the 50-day moving average and uptrend support (blue line). Below, and $4.50 is back on the table. Top Stock Trades for Tomorrow No. 3: JD.com (JD)Source: Chart courtesy of StockCharts.comAbove is a multi-year, weekly chart of JD.com (NASDAQ:JD), which shows the impressive bullish volume in the stock over the past few quarters. The stock hammered out a nice bottom near $20 in late 2018, and has been working higher ever since.For most of 2019, JD.com was setting up in a beautiful long-term ascending triangle. That's where rising uptrend support (blue line) squeezes a stock against a static level of resistance. The latter came into play near $32 and the 200-week moving average.Bulls got what they were looking for in the form of a big-time breakout. JD has since reclaimed $36, and continues to rise. If it can maintain this week's gain, investors are looking at a bullish, engulfing candle -- suggesting more upside could be in store. * 7 Energy ETFs to Buy for a Rebound in 2020 Over $42, and the $44 to $46 range is on the table. Historically, JD.com has struggled above this area. Above it, and $50 is possible. Below $39, and perhaps we can get a test of $36. Should the market really unravel, I'd love to scoop JD up at $32. Top Stock Trades for Tomorrow No. 4: Virgin Galactic (SPCE)Source: Chart courtesy of StockCharts.comYou want to talk about volume, though? Just check out the profile on Virgin Galactic (NYSE:SPCE). This stock continues to erupt higher and higher, leaving the stratosphere.We flagged the stock on its breakout over $12, paving the way to some tremendous gains, although I have been more cautious on the name north of $15. Like I said then, there could certainly be more upside, but no way can we be buyers here near $20 when SPCE was at $11 just a few days ago.Maybe we can buy a pullback, if there are signs that bulls still have momentum. Otherwise, we could see this one blow its top off and then fizzle.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long APHA. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy as the 2020 Presidential Election Approaches * 5 Dividend Stocks With Low Payout Ratios and High Yields * 4 Post-Holiday Retail Stocks Still Worth a Look The post 4 Top Stock Trades for Thursday: BA, APHA, JD, SPCE appeared first on InvestorPlace.
A survey of the provincial board’s online stores presented a more concentrated market for cannabis 2.0 products than for dried flower, Cantor Fitzgerald analyst Pablo Zuanic said in a Tuesday report. The ...
Aphria Inc. shares rallied more than 6% Tuesday, after a bullish analyst note and news that the company has achieved GMP status in the European Union, clearing the path for it to start selling medical cannabis to pharmacies in Germany and other countries.
Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) today announced that it has received its European Union Good Manufacturing Practices ("EU GMP") certification as an active substance manufacturer in accordance with Art.111 of Directive 2001/83 EC from the Malta Medicines Authority ("MMA") at the Company's Aphria One facility in Leamington, Ontario.
Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) today announced that it has received its European Union Good Manufacturing Practices ("EU GMP") certification in respect of medicinal products for human use and investigational medicinal products for human use, from the Malta Medicines Authority ("MMA") at the Company's subsidiary, ARA - Avanti Rx Analytics.
Cannabis Countdown: Top 10 Marijuana Stock News Stories of the Week Welcome to the Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for ...
(Bloomberg) -- Tough times in the cannabis industry aren’t stopping its leaders from going to Davos.For the second year in a row, there will be a Cannabis House in Davos, Switzerland this week alongside the schmoozing and speeches of the World Economic Forum. The 2020 offering promises to be “a little more formal and more professional” than last year’s, according to Jason Paltrowitz, executive vice president of corporate services at OTC Markets Group, one of the sponsors of the Cannabis House.Cannabis House will feature a two-day conference focused on the themes of Davos 2020, including sustainability, climate change, social equity and impact investing.The rout in pot stocks hasn’t dampened interest in the event, which will also include “a professional capital markets discussion,” Paltrowitz said.The agenda has an international flavor, with speakers from Israel, Switzerland and Asia.The goal is to get delegates from the World Economic Forum to pop in and learn about the industry, said Richard Carleton, chief executive officer of the Canadian Securities Exchange, another sponsor.“What was particularly interesting to me last year was how many European institutional investors, everybody from family office managers, hedge funds, right up to some of the largest pension funds in the world” stopped by Cannabis House, Carleton said. “They hadn’t invested yet but were there to learn.”Stock ReboundInvestors seemed to be in the mood to celebrate successes rather than punish failures last week.Pot stocks ended the week significantly higher, with the BI Global Cannabis Competitive Peers Index up 15% and the Canadian-focused Horizons Marijuana Life Sciences Index ETF adding 18%, its biggest weekly increase since August 2018. The gains came despite Aphria Inc.’s earnings miss and cut to its full-year guidance, which sent its shares down 8.6% on Tuesday.Instead, investors focused on positive results from Aphria’s smaller competitor Organigram Holdings Inc. Organigram’s U.S.-traded shares surged 45% Wednesday after it reported positive adjusted Ebitda and revenue that beat the highest analyst estimate. That sent the entire sector rallying, and even Aphria’s shares ended the week higher.Given how fast investors have been to punish missteps in recent months, could this be a sign that the sector has bottomed out?There are positive signs in the capital markets too, according to data from Viridian Capital Advisors. In the first two weeks of 2020, seven capital raises worth a total of $250 million were completed. Although the number of deals was lower than the 15 done in the first two weeks of 2019, the average deal size was more than 2.5 times bigger than the same period of last year, Viridian said.Events This WeekMONDAY 1/20Cannabis House hosts “a global cannabis conversation” in Davos, Switzerland alongside the World Economic Forum, through Jan. 21U.S. markets closed for Martin Luther King Jr. DayWEDNESDAY 1/22CannaWest addresses regulatory issues in the industry; the event runs in Los Angeles through Jan. 24THURSDAY 1/23A one-day Cannabis Conclave will be held in Davos, SwitzerlandLast Week’s Top StoriesOrganigram Surge Lifts Sector Despite Lingering UncertaintyCanopy Delays Cannabis Beverage Launch at Most Inopportune TimeBirthplace of Semi-Legal Pot Risks Falling Behind U.S.Congress Wants More People Growing Pot for Cannabis ResearchTo contact the reporter on this story: Kristine Owram in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Brad Olesen at email@example.com, Will DaleyFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
What a week for cannabis stocks! Finally rebounding, ETFs inched alongside many big companies in the industry. Over the last five trading days: The Horizons Marijuana Life Sciences Index ETF (OTC: HMLSF ...
You hear that? That's the sound of the beginning of a big rebound in marijuana stocks. Year-to-date, the ETFMG Alternative Harvest ETF (NYSEARCA:MJ) is already up almost 10% -- and we are less than three weeks into the year. That's a huge gain in a short amount of time.The big rebound in pot stocks can be attributed to favorable fundamental developments (multiple cannabis companies have reported strong fourth quarter numbers in early January), favorable legal developments (among other things, Illinois just legalized recreational marijuana), and a whole bunch of investors deciding that with the new year, comes new opportunity.That's the good news for cannabis bulls. The better news? This big rebound in marijuana stocks is just getting started.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOver the next several quarters, everything is going to improve for the cannabis sector. Demand trends will re-accelerate thanks to new vapes and edibles products, as well as retail footprint expansion. Supply overhang issues will ease with rebounding demand. International markets will start to take off as governments around the world follow in Canada's footsteps. Revenue growth trends will improve. Margins will bounce back. Losses will narrow.All in all, things will just get better for the cannabis sector in 2020, and as they do, depressed and beaten-up pot stocks will rebound. * The Top 5 Dow Jones Stocks to Buy for 2020 With that in mind, let's take a deeper look at four marijuana stocks to buy for the big 2020 rebound. Canopy Growth (CGC)Source: Shutterstock The cannabis market's biggest and most important company, Canopy Growth (NYSE:CGC), has been leading the pot stock rebound in 2020 so far. Year-to-date, CGC stock is up more than 15%.Canopy will continue to be a leader in this rebound for the rest of 2020 for one very simple reason: this is the best cannabis company out there by a mile.They have the biggest balance sheet -- thanks to a multi-billion dollar investment from Constellation Brands (NYSE:STZ) -- with the most resources and firepower to invest in things like product development, international expansion, strategic acquisitions, and production build-out. They also have the biggest sales base, the most production capacity, and the widest global distribution network.The management team is arguably the best in the business, as Constellation has infused the company with experienced talent. They also have the most visible pathway to dominating the ultra-valuable U.S. market, thanks to a planned acquisition of U.S. cannabis company Acreage.All in all, Canopy Growth has significantly differentiated itself from the pack in the cannabis world. As the leader, if pot stocks keep rebounding throughout the rest of the year, CGC stock will lead that rebound. Cronos (CRON)Source: Shutterstock The only other "high quality" cannabis company that has won the multi-billion dollar support of a consumer staples giant is Cronos (NASDAQ:CRON). This unique feature should propel meaningful out-performance in CRON stock in 2020.Cannabis market trends will rebound in 2020 thanks to new products, retail footprint expansion, favorable legislative progress, and international growth, among other things. As those trends rebound, investors will rush back into the marijuana industry like its early 2019 all over again.When investors flocked into the space back then, they did most of that flocking into two names -- Canopy and Cronos -- because those were the smartest and safest investments given their fortified balance sheets, huge investment capability, and tremendous financial support. Of note, Cronos stock outperformed Canopy stock in the first three months of 2019 by a tally of 80% to 60%, mostly thanks to the fact that CRON stock was cheaper than CGC stock (15-times one-year forward sales for CRON, versus 30-times for CGC at the beginning of 2019). * 10 Cheap Stocks to Buy Under $10 In 2020, the same dynamic will repeat. Investors will rush back into the space amid improving fundamentals and trends. They will specifically rush back into the smartest and safest investments in the space, CRON and CGC. And CRON will be the bigger winner, because CRON stock (9-times one-year forward sales) remains way cheaper than CGC stock (14-times one-year forward sales). Aphria (APHA)Although most pot stocks are up big in early 2020, shares of cannabis producer Aphria (NYSE:APHA) are not, mostly because the company reported second quarter numbers in January that missed across the board. Revenues missed estimates, as did profits. And management dramatically cut its full-year guide.Consequently, APHA stock is actually down 1% in 2020, while many of its marijuana peers are up 10% or more.This weakness won't last. It's a gross overreaction to a few headline second quarter misses. Underneath those misses, the numbers were actually pretty good. Revenue growth accelerated sequentially, from up 8% quarter-over-quarter in Q1 to up 9% quarter-over-quarter in Q2. Volume growth also accelerated, and by way more, going from 7% growth in Q2, to 18% growth in Q2. Gross margins reversed course, after dropping from 53% in Q4 to 50% in Q1, and shot back up to 57% in Q2. At the same, Aphria reported a huge sequential increase in adjusted EBITDA after a sequential drop in Q1.In other words, all of the company's important underlying trends improved meaningfully in the second quarter. Revenue, volume, margin, and profit trends all got better.And that's before the launch of new vapes and edibles products. As such, the numbers will only get better in the third and fourth quarters. As they keep improving, investors will push APHA stock way higher, especially considering its relatively depressed valuation base (2-times one-year forward sales). Aurora (ACB)Source: Shutterstock Last, but not least, on this list of marijuana stocks to buy for the big rebound in 2020 is Aurora (NYSE:ACB).Aurora has long been the second-biggest player in the Canadian cannabis market, coming in right behind Canopy in terms of sales, volume, and production capacity. But investors have increasingly expressed concerns over the company's balance sheet and liquidity, as Aurora features one of the worst balance sheets in the cannabis sector and has a major cash burn problem.Ultimately, these concerns have kept ACB stock depressed. These concerns could ease dramatically in 2020. Aurora will launch of suite of edibles and vapes products over the coming months. They should also be opening a ton of new stores.This combination will reignite demand trends at Aurora, and revenue growth rates should start improving. As they do, more favorable supply-demand dynamics will push up margins. Bigger revenues plus bigger margins equals smaller losses. Smaller losses mean less cash burn.As cash burn becomes less of a problem in 2020 (and as the company's improved revenue growth trajectory illuminates a more visible pathway towards profitability), investors will become less concerned about the company's balance sheet and liquidity. The more those concerns fade, the more ACB stock will rally.As of this writing, Luke Lango was long CGC. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The Top 5 Dow Jones Stocks to Buy for 2020 * 7 Fintech ETFs to Buy Now for Fabulous Financial Exposure * 3 Tech Stocks to Play Ahead of Earnings The post 4 Marijuana Stocks to Buy for the Big 2020 Rebound appeared first on InvestorPlace.
Following a disastrous performance in 2019, marijuana stocks are staging a huge comeback in early 2020. So far this year, the ETFMG Alternative Harvest ETF (NYSEARCA:MJ) is already up about 10%, representing an impressive average gain per trading day of nearly 1%.Leading the charge are the usual suspects. So far this month, Canopy Growth (NYSE:CGC) is up 15%. Tilray (NASDAQ:TLRY) has gained 19%. and Cronos (NASDAQ:CRON) has added 6%.But one marijuana stock missing out on this party is Aphria (NYSE:APHA). Best known as the only cannabis company to report a quarterly profit so far, APHA has not rebounded with its peers in 2020. Instead, Aphria stock is flat in 2020.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis relative underperformance of APHA stock won't last.Aphria's trends are too favorable, its fundamentals too good, and its valuation too discounted to keep Aphria stock depressed for much longer. As marijuana stocks continue to rebound throughout 2020 amid favorable cannabis trends, Aphria stock will turn into the one of the segment's hottest stocks. Indeed, my estimates indicate that Aphria stock could more than double this year.Here's how that could happen. Marijuana Stocks Will Keep ReboundingCentral to the bull thesis on APHA stock is the idea that the entire cannabis sector will rebound dramatically in 2020.Three positive catalysts will drive that rebound. First, the currently depressed demand trends of Canada's legal cannabis market will improve significantly in 2020. The factors that will bring about its improvement are the introduction of new edibles and vape products, more aggressive launches of new stores, and logistical improvements by legal suppliers and distributors. The demand rebound will turn falling revenue growth rates across the whole industry into rising revenue growth rates. * The Top 5 Dow Jones Stocks to Buy for 2020 Second, the supply glut of Canada's legal market will ease due to accelerating demand trends. Economics 101 teaches that falling supply and rising demand lead to higher prices. Higher prices create higher margins. Consequently, the cannabis industry's margin weakness of 2019 could turn into margin strength in 2020.Third, various cannabis markets outside of Canada will gain traction and turn into meaningful revenue contributors for legal suppliers. That is, governments around the world will adopt more lenient marijuana laws, thanks to increasing pressure by consumers for such laws. As that happens, more countries will legalize cannabis in 2020. At the same time, more and more states across the U.S. will legalize marijuana, and more and more Canadian cannabis companies will jump into the U.S. market.The marijuana industry seems optimally positioned for a huge rebound in 2020, meaning that the recent strength of the sector's stocks will most likely persist. Aphria Stock Will Join The RallyAphria stock is currently sitting out the big rally by cannabis stocks. That won't last forever. Soon enough, Aphria will join the rally, and when it does, Aphria stock could explode higher.Investors have been relatively bearish on Aphria recently because the company's second-quarter earnings report, delivered in early January, missed analysts' average expectations, and the company, in conjunction with the results, cut its full-year revenue and profit guidance. But the miss doesn't tell the whole story.Aphria's trends are actually pretty good. Its quarter-over-quarter cannabis revenue growth and its QoQ cannabis volume growth accelerated compared with Q1's rates. Those two data points imply that demand for Aphria's cannabis is rising. At the same time, its cannabis gross margins improved tremendously, rising from 50% in Q1 to 57% in Q2. The data supports the idea that improving supply-demand dynamics are meaningfully lifting Aphria's margins.Aphria has all the momentum it needs to join the marijuana stock rally, as demand for its products is accelerating and its margins are expanding.Eventually, these improving growth trends, combined with the massively discounted valuation of APHA stock, will produce an epic rally by the shares.Analysts, on average, expect Aphria's fiscal 2022 earnings per share to be 40 cents. That estimate will prove to be conservative. My modeling indicates that improving demand and margin drivers will push the company's FY22 EPS to 50 cents or higher. Based on a forward earnings multiple of 20, which is average for growth stocks, my 2021 price target for Aphria stock is $10.The shares closed at $5.19 yesterday. The Bottom Line on APHA StockAphria stock has sat out the 2020 marijuana stock rally so far, but it won't remain on the sidelines forever. Instead, as soon as worries about the Q2 earnings report fade, the shares will start to climb higher. Given how cheap this stock is and how good APHA's fundamentals are, the rally will be huge and could reach 100%.As of this writing, Luke Lango was long CGC. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The Top 5 Dow Jones Stocks to Buy for 2020 * 7 Fintech ETFs to Buy Now for Fabulous Financial Exposure * 3 Tech Stocks to Play Ahead of Earnings The post Here's How Aphria Stock Could Double in 2020 appeared first on InvestorPlace.
As the cannabis stocks trade at multi-year lows, the market is looking to grasp at any positive news from the upcoming earnings season. Any positive news from Q4 sales or insights on the Cannabis 2.0 rollout in Canada will breath some relief into the market.The North American cannabis industry has plenty of catalysts by midyear 2020, but the related companies were built for robust revenues and much larger markets. The keys to watch in the upcoming earnings reason are the ability of cannabis companies to generate profits from the current market opportunities and not the previous grand expectations.Several big catalysts for cannabis revenue growth in 2020 include CBD in the U.S., Cannabis 2.0 rollout in Canada, additional retail stores in Ontario and the approval of recreational cannabis in U.S. states such as Illinois. Not to mention, the U.S. always has the potential for the federal government to approve cannabis allowing for the ultimate prize for cannabis companies and investors alike.The market projections for the global cannabis market reaching $200 billion in the future should stand. For now, cannabis stocks in Canada and the U.S. have to focus on maintaining liquidity to survive and eventually thrive in the disappointing sales ramp in North America and around the globe. A lot of the Canadian issues should resolve themselves over the next few quarters, but the illicit market remains a formidable competitor and investors shouldn’t assume the profit picture improves dramatically in the near term with so much competition.We’ve delved into three cannabis companies that recently reported quarterly results through November 30 with commentary covering the early part of January. Using TipRanks' Stock Comparison tool, we lined up the three alongside each other to give us an idea of what the Street thinks is in store for the trio in the year ahead.Aphria (APHA)The most influential earnings report of early January was Aphria. The company is one of the larger Canadian cannabis LPs and provides a good indication of market demand into the first couple of weeks of January.The good news is Aphria grew net cannabis revenues by 9% sequentially for the quarter ending November 30. The bad news is that the cannabis company cut FY20 revenue guidance by an astounding $75 million.The revenue cut wasn’t a huge shock to the market considering the Ontario regulators pushed new retail store openings out until April and Aphria has a fiscal year ending in May. This timing issue combined with vape bans in Alberta and Quebec and the possibility of a major revenue ramp up this fiscal year was near impossible.For FQ2, the company reported revenue declined by C$5.5 million to C$120.6 million. The major revenue hit came from a reduction of distribution revenue in Germany.The stock dipped 8% on the news to $5 based on the revenue cut and the hit to EBITDA targets. Aphria now expects FY20 EBTIDA of only C$35 million to C$42 million, down from an estimate of over C$90 million.The company remains one of the rare Canadian companies generating positive EBITDA due to reasonable operating expenses, but the market needs to absorb this revenue cut before the stock can rally this year.All in all, Wall Street is split between the bulls and those who are more cautious on the cannabis player, with TipRanks analytics exhibiting APHA as a Moderate Buy. Out of 4 analysts tracked in the last 3 months, 2 are bullish on Aphria stock while 2 remain sidelined. With a return potential of 23%, the stock's consensus target price stands at $6.36. (See Aphria stock analysis at TipRanks)OrganiGram (OGI)OrganiGram had one of the better reports in the cannabis sector in the last few quarters. The stock has soared over 45% on the news, yet OrganiGram isn’t even back to the highs from November.For the quarter ending in November, the Canadian cannabis company reported net revenues of C$25.2 million. The amount beat estimates, but the company is still below the revenue levels from mid-2019 and the beat occurred due to low calorie wholesale revenues of C$9.5 million.The rally is more of a relief that the numbers didn’t get worse despite investor knowledge that monthly cannabis sales in Canada have slowly improved throughout the year. In addition, OrganiGram generated quarterly EBITDA of C$4.9 million for a 9% EBITDA margin.The company has a fully diluted market cap of $500 million with a FY21 sales target in the $170 million range. The stock trades at a reasonable 3x forward sales, but OrganiGram only has a minimal C$34 million cash balance and already has C$85 million in debt.The company forecasts having enough capital to fund operations and capital expenditure plans, but those plans include rolling out Cannabis 2.0 products in 2020 and further facilities. Investors should expect OrganiGram to take advantage of this stock rally to $3 to utilize the at-the-market equity program to raise the C$32 million available under the program after raising C$23 million subsequent to quarter end.Where does the Street side on this cannabis producer? It appears mostly bullish. Out of 10 analysts polled by TipRanks in the last 3 months, 6 are bullish on OrganiGram stock while 3 remain sidelined and one is bearish. With a return potential of nearly 43%, the stock’s consensus target price stands at $4.73. (See OrganiGram stock analysis at TipRanks)KushCo (KSHB)KushCo provided an alternative view to the cannabis sector as the company is focused on providing products and services to the U.S. cannabis market. The company took a revenue hit in the last quarter from the health concerns in the U.S. vape market.Quarterly revenues were up 38% from last year to $35 million, but the numbers were down from the $47 million reported in the prior quarter. KushCo missed analyst estimates by a wide margin as customers reduced vape inventory levels in fears of bans by state regulators.The company still guided to full year revenues of $240 million in expectations that customer orders catch up over the remaining three quarters of the year. KushCo laid off 53 people in order to improve the profitability picture after reporting a $12.5 million loss in the quarter, but the employee reduction only saves ~$4.3 million in annual savings.The stock has a minimal market valuation of $175 million, but the tough market and limited margins should leave investors on the sidelines here. KushCo continues to lose too much money and only ended the November quarter with a cash balance below $15 million.To find good ideas for cannabis stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
TORONTO , Jan. 16, 2020 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA), a leading global cannabis company, is combating winter blues and energizing the public with the launch of a Plant Positivity Winter Garden on Monday, January 20 , known to some as Blue Monday — the most depressing day of the year based on factors such as weather conditions, debt levels and low motivation levels. With a vision to improve quality of life for communities and individuals, Aphria's social impact platform, Plant Positivity, provides people with greater access to green spaces and creates opportunities to learn about plants and plant care.
Organigram shares soared more than 35% Wednesday and helped lift the broader cannabis sector higher, after the company’s first-quarter revenue more than doubled and beat analyst estimates.
Canadian cannabis company Aphria Inc.'s shares rose 2.4% in premarket trade Wednesday, after CIBC upgraded the stock to neutral from underperform and said it is more constructive on the stock now that an inevitable cut to guidance has been announced. "There will be issues to contend with, such as ongoing elevated capex spend and substantial working capital investments," analysts John Zamparo and Krishna Ruthnum wrote in a note. "But the balance sheet is relatively strong and market share gains are encouraging." The analysts raised their price target on the stock to C$7.00 ($5.36) from C$6.50. The company's revised guidance--it now expects 2020 revenue of C$575 million to C$625 million versus earlier guidance of C$650 million to C$700 million--is "much more achievable" although it may not be conservative enough, the analysts wrote. But with consensus below the new range, future guidance risk has moderated, said the note. Aphria shares have fallen 25.5% in the last 12 months, while the ETFMG Alternative Harvest ETF has fallen 41%. The S&P 500 has gained 26%.